260 related articles for article (PubMed ID: 31536779)
21. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
Xu L; Qi Y; Xu Y; Lian J; Wang X; Ning G; Wang W; Zhu Y
Oncotarget; 2016 Jun; 7(24):36235-36246. PubMed ID: 27105537
[TBL] [Abstract][Full Text] [Related]
22. Effects of Sorafenib, a Tyrosin Kinase Inhibitor, on Adrenocortical Cancer.
Cerquetti L; Bucci B; Raffa S; Amendola D; Maggio R; Lardo P; Petrangeli E; Torrisi MR; Toscano V; Pugliese G; Stigliano A
Front Endocrinol (Lausanne); 2021; 12():667798. PubMed ID: 34108938
[TBL] [Abstract][Full Text] [Related]
23. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
24. Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma.
Germano A; Rapa I; Duregon E; Votta A; Giorcelli J; Buttigliero C; Scagliotti GV; Volante M; Terzolo M; Papotti M
Endocr Pathol; 2017 Jun; 28(2):95-102. PubMed ID: 28271381
[TBL] [Abstract][Full Text] [Related]
25. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.
De Martino MC; van Koetsveld PM; Feelders RA; Sprij-Mooij D; Waaijers M; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ
Endocr Relat Cancer; 2012 Jun; 19(3):351-64. PubMed ID: 22420007
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study.
Libé R; Borget I; Ronchi CL; Zaggia B; Kroiss M; Kerkhofs T; Bertherat J; Volante M; Quinkler M; Chabre O; Bala M; Tabarin A; Beuschlein F; Vezzosi D; Deutschbein T; Borson-Chazot F; Hermsen I; Stell A; Fottner C; Leboulleux S; Hahner S; Mannelli M; Berruti A; Haak H; Terzolo M; Fassnacht M; Baudin E;
Ann Oncol; 2015 Oct; 26(10):2119-25. PubMed ID: 26392430
[TBL] [Abstract][Full Text] [Related]
27. The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line.
Pezzani R; Rubin B; Bertazza L; Redaelli M; Barollo S; Monticelli H; Baldini E; Mian C; Mucignat C; Scaroni C; Mantero F; Ulisse S; Iacobone M; Boscaro M
Invest New Drugs; 2016 Oct; 34(5):531-40. PubMed ID: 27177645
[TBL] [Abstract][Full Text] [Related]
28. STMN1 is Overexpressed in Adrenocortical Carcinoma and Promotes a More Aggressive Phenotype In Vitro.
Aronova A; Min IM; Crowley MJP; Panjwani SJ; Finnerty BM; Scognamiglio T; Liu YF; Whitsett TG; Garg S; Demeure MJ; Elemento O; Zarnegar R; Fahey TJ
Ann Surg Oncol; 2018 Mar; 25(3):792-800. PubMed ID: 29214451
[TBL] [Abstract][Full Text] [Related]
29. Metformin as a new anti-cancer drug in adrenocortical carcinoma.
Poli G; Cantini G; Armignacco R; Fucci R; Santi R; Canu L; Nesi G; Mannelli M; Luconi M
Oncotarget; 2016 Aug; 7(31):49636-49648. PubMed ID: 27391065
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.
Berruti A; Sperone P; Ferrero A; Germano A; Ardito A; Priola AM; De Francia S; Volante M; Daffara F; Generali D; Leboulleux S; Perotti P; Baudin E; Papotti M; Terzolo M
Eur J Endocrinol; 2012 Mar; 166(3):451-8. PubMed ID: 22189997
[TBL] [Abstract][Full Text] [Related]
31. Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma.
Liang R; Weigand I; Lippert J; Kircher S; Altieri B; Steinhauer S; Hantel C; Rost S; Rosenwald A; Kroiss M; Fassnacht M; Sbiera S; Ronchi CL
Front Endocrinol (Lausanne); 2020; 11():219. PubMed ID: 32373071
[TBL] [Abstract][Full Text] [Related]
32. The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures.
van Koetsveld PM; Creemers SG; Dogan F; Franssen GJH; de Herder WW; Feelders RA; Hofland LJ
J Clin Endocrinol Metab; 2020 Feb; 105(2):407-17. PubMed ID: 31586196
[TBL] [Abstract][Full Text] [Related]
33. GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo.
Chimento A; Sirianni R; Casaburi I; Zolea F; Rizza P; Avena P; Malivindi R; De Luca A; Campana C; Martire E; Domanico F; Fallo F; Carpinelli G; Cerquetti L; Amendola D; Stigliano A; Pezzi V
Oncotarget; 2015 Aug; 6(22):19190-203. PubMed ID: 26131713
[TBL] [Abstract][Full Text] [Related]
34. MECHANISMS OF ENDOCRINOLOGY: Cell cycle regulation in adrenocortical carcinoma.
Pereira SS; Monteiro MP; Bourdeau I; Lacroix A; Pignatelli D
Eur J Endocrinol; 2018 Aug; 179(2):R95-R110. PubMed ID: 29773584
[TBL] [Abstract][Full Text] [Related]
35. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
[TBL] [Abstract][Full Text] [Related]
36. Chloroquine enhances the efficacy of cisplatin by suppressing autophagy in human adrenocortical carcinoma treatment.
Qin L; Xu T; Xia L; Wang X; Zhang X; Zhang X; Zhu Z; Zhong S; Wang C; Shen Z
Drug Des Devel Ther; 2016; 10():1035-45. PubMed ID: 27022243
[TBL] [Abstract][Full Text] [Related]
37. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
[TBL] [Abstract][Full Text] [Related]
38. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
[TBL] [Abstract][Full Text] [Related]
39. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
[TBL] [Abstract][Full Text] [Related]
40. Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study.
Fiorentini C; Fragni M; Perego P; Vezzoli S; Bonini SA; Tortoreto M; Galli D; Claps M; Tiberio GA; Terzolo M; Missale C; Memo M; Procopio G; Zaffaroni N; Berruti A; Sigala S
J Clin Endocrinol Metab; 2016 Dec; 101(12):4594-4602. PubMed ID: 27626976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
